Colorectal Cancer Trial: Duloxetine Didn't Prevent Oxaliplatin Neuropathy

Alliance A221805 study finds antidepressant did not successfully prevent chemotherapy-induced nerve damage

Apr. 10, 2026 at 8:07pm

Got story updates? Submit your updates here. ›

An abstract, ghostly X-ray image revealing the internal structure of a chemotherapy medication capsule, conceptually representing the complexities of managing cancer treatment side effects.The Alliance A221805 trial's findings underscore the ongoing challenge of managing chemotherapy's side effects, as researchers continue to explore innovative solutions to improve patient outcomes.Minneapolis Today

A recent clinical trial, the Alliance A221805 study, has revealed that the antidepressant duloxetine did not effectively prevent oxaliplatin-induced peripheral neuropathy in colorectal cancer patients undergoing chemotherapy. The study, led by Dr. Ellen M. Lavoie Smith, aimed to determine if duloxetine could serve as a preventive measure for this common and debilitating side effect of cancer treatment.

Why it matters

Managing the side effects of cancer treatment, particularly chemotherapy-induced neuropathy, is a critical aspect of patient care. This study provides valuable insights into the limitations of using duloxetine as a preventive measure, highlighting the need for continued research and the development of more effective strategies to address this challenging problem.

The details

The Alliance A221805 trial enrolled colorectal cancer patients who were receiving oxaliplatin-based chemotherapy. Participants were randomly assigned to receive either duloxetine or a placebo. The researchers assessed the development of sensory neuropathy over the course of the study. Unfortunately, the results showed no significant difference in the incidence of neuropathy between the two groups, indicating that duloxetine did not successfully prevent this side effect.

  • The Alliance A221805 trial was conducted between 2022 and 2025.
  • The study results were published in the journal JCO Oncology Advances in April 2026.

The players

Dr. Ellen M. Lavoie Smith

The lead researcher of the Alliance A221805 trial, which investigated the use of duloxetine to prevent chemotherapy-induced neuropathy in colorectal cancer patients.

Alliance A221805

A clinical trial sponsored by the Alliance for Clinical Trials in Oncology, a national network of researchers and cancer centers that conducts large-scale cancer clinical trials.

Got photos? Submit your photos here. ›

What they’re saying

“While duloxetine remains a viable option for managing painful neuropathy, its preventive role needs further exploration.”

— Duncan Muller, Author

What’s next

Researchers will continue to investigate alternative strategies and therapies to prevent and manage chemotherapy-induced neuropathy, as this remains a significant challenge in cancer care.

The takeaway

This study highlights the complexities of managing the side effects of cancer treatment and the ongoing need for innovative solutions to improve the quality of life for patients undergoing chemotherapy.